AUM Biosciences Doses First Patient In Phase 2 Clinical Trial Of AUM001 In Metastatic Colorectal Cancer
Portfolio Pulse from Happy Mohamed
AUM Biosciences has dosed its first patient in a Phase 2 clinical trial for AUM001, a treatment for metastatic colorectal cancer. The trial is being conducted in collaboration with MSD, a tradename of Merck & Co., Inc. AUM Biosciences plans to merge with Mountain Crest Acquisition Corp. V (NASDAQ:MCAG) and trade on the Nasdaq under the ticker symbol AUMB.
May 30, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AUM Biosciences plans to merge with Mountain Crest Acquisition Corp. V (NASDAQ:MCAG) and trade on the Nasdaq under the ticker symbol AUMB.
The successful dosing of the first patient in AUM Biosciences' Phase 2 clinical trial is a positive development for the company and its planned merger with Mountain Crest Acquisition Corp. V. This news may increase investor interest in MCAG, as the merger will result in AUM Biosciences trading on the Nasdaq under the ticker symbol AUMB.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
AUM Biosciences is collaborating with MSD, a tradename of Merck & Co., Inc. (NYSE:MRK), for the Phase 2 clinical trial of AUM001.
The collaboration between AUM Biosciences and Merck & Co. for the Phase 2 clinical trial of AUM001 demonstrates Merck's involvement in the development of innovative cancer treatments. This partnership may have a positive impact on Merck's stock price, as it showcases the company's commitment to advancing oncology therapeutics.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 80